FDA approves extension of Eylea HD dosing intervals

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related macular degeneration, Regeneron Pharmaceuticals, Inc. announced.
The approval, which extended the dosing intervals up to every 20 weeks, also includes an update to the Eylea HD (aflibercept 8 mg, Regeneron) label to include 2-year data from “the pivotal” PULSAR and PHOTON trials, according to a press release.
“The potential for needing only two or three Eylea HD injections a year to manage certain retinal diseases is an exciting advance that could benefit








